Skip to content
OpenCapital
Get started

Milestone Pharmaceuticals MIST Q4 2025 Annual earnings

Reported March 20, 2026 · Before market open

Revenue$1.5MMiss by $36.0MDiluted EPS-$0.16Beat by $0.02
Revenue estimate$37.5M
EPS estimate-$0.18

Next report

Aug 12, 2026 (in a month)
Revenue estimate$1.1M
EPS estimate-$0.18

Versus estimates

Revenue

Q1 2026$238.0KMiss by $29.9M
Q4 2025$1.5MMiss by $36.0M

Diluted EPS

Q1 2026-$0.20Miss by $0.26
Q4 2025-$0.16Beat by $0.02
Q3 2025-$0.12Beat by $0.05Q2 2025-$0.20Miss by $0.02Q1 2025-$0.31Miss by $0.12Q4 2024-$0.19Miss by $0.04

Ask the moment Milestone Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Milestone Pharmaceuticals report Q4 2025 earnings?
Milestone Pharmaceuticals (MIST) reported Q4 2025 earnings on March 20, 2026 before market open.
What were Milestone Pharmaceuticals's Q4 2025 revenue and EPS?
Milestone Pharmaceuticals reported revenue of $1.5M and diluted EPS of $-0.16 for Q4 2025.
Did Milestone Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $37.5M by $36.0M. EPS beat the consensus estimate of $-0.18 by $0.02.
How did Milestone Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 15.8% from $-0.19.
Where can I find Milestone Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-032427) and the 10-K periodic report (0001104659-26-032415) directly on SEC EDGAR. The filing index links above go to sec.gov.